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Background
Even though, Highly Active Antiretroviral Therapy
(HAART) has resulted in significant reduction in mor-
tality associated with Acquired Immune Deficiency Syn-
drome (AIDS), the side-effects and difficulties in patient
compliance warrants the search for new therapeutic
options. One potential strategy is to design chemokine
analogues that will prevent the entry of human immu-
nodeficiency virus-1 (HIV-1) into the target cell by com-
petitively blocking its interaction with CC chemokine-5
(CCR5) receptor. The objective of the present study is
to design and validate the efficacy of chemokine analo-
gues based on the viral macrophage inflammatory pro-
tein-II (vMIP-II) core as putative anti-HIV agents.
Methods
In the present study we have synthesized the chemokine
analogues by Fmoc solid phase peptide synthesis and
were purified to homogeneity by semi preparative RP-
HPLC. Molecular mass of the analogues were confirmed
by MALDI-TOF MS. Structural characterization was
done by CD spectroscopy. Their interaction with CCR5
receptor was analyzed by calcium release studies.
Results
The analogues designed were obtained in high purity
and correct identity and they displayed similar patterns
on the CD spectra to their parent template vMIP-II.
The analogues displayed significantly lower toxicity in
MTT assays. The interactive nature of the analogues
was evident in calcium release studies where, the cal-
cium flux varies with the type of the grafted N-terminus.
Conclusion
The findings in this study highlight the potential of
vMIP-II to serve as a valuable target in designing che-
mokine analogues, which have the efficiency to serve as
putative anti HIV- 1 agents.
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